NEW YORK, Oct. 26, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of XBiotech, Inc. (NASDAQ:XBIT) between April 15, 2015 and April 20, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Price v. XBiotech, Inc., et al. (Case No. 1:17-cv-01023) in the USDC for the Western District of Texas, Austin Division. Click here to view the complaint. To get more information go to:
http://www.zlk.com/pslra-sbm/xbiotech-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the results of its European Phase III trial for the treatment of colorectal cancer with Xilonix were inconclusive; (2) the Company misrepresented the endpoint used in the European Study; (3) the Company’s claim of a 76% increase in improvement was misleading and represented a relative improvement rate; (4) ultimately, the Companies’ studies would not support the approval of the application with the EMA; and (5) as a result of the foregoing, Defendants’ statements about its business and operations were materially false and misleading at all relevant times.
If you suffered a loss in XBiotech you have until December 26, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Anta Sports Expands Global Footprint With Strategic Puma Stake
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 



